方法：本研究包含初诊为原发性开角型青光眼(POAG)或剥脱性青光眼(PXG)患者24例37眼。采用Goldmann压平眼压计测量IOP，超声测厚仪测量CCT，超声生物测量仪测量ACD和ACD/轴长(AL)。比较治疗前，记录治疗后3mo和6mo的IOP，CCT，ACD和ACD/AL测量值。

结果：IOP于治疗前，治疗后3mo、6mo平均值分别为25.0±4.2、17.5±2.0、16.9±1.7，可见治疗后显著降低。CCT于治疗前，治疗后3mo、6mo平均值分别为546.6±31.5， 541.0±29.4、542.2±29.3，可见治疗后显著降低。ACD于治疗前，治疗后3mo、6mo平均值分别为3.00±0.43，2.95±0.42、2.97±0.41，可见治疗后3mo显著降低，6mo无显著改变。ACD/AL治疗后改变与ACD情况相似。CCT和ACD的测量值在POAG中有显著变化，而在PXG中则没有。

结论：开角型青光眼患者应用拉坦前列素滴眼液治疗后，除IOP大幅降低外，角膜厚度及ACD亦出现短期内降低。

METHODS:Thirty seven eyes of 24 newly diagnosed patients with primary open-angle glaucoma(POAG)or pseudoexfoliation glaucoma(PXG)were included. IOP was measured with Goldmann applanation tonometry, CCT was measured with ultrasound pachymeter, while ACD and ACD/axial length(AL)values were obtained by ultrasound biometry. IOP, CCT, ACD and ACD/AL measurements before treatment were compared with the recordings at the 3mo and the 6mo of treatment.

RESULTS: Mean IOP values at baseline, and at 3mo and 6mo were, 25.0±4.2, 17.5±2.0 and 16.9±1.7, respectively, showing a significant reduction after treatment. Mean CCT values at baseline, and at 3mo and 6mo were, 546.6±31.5, 541.0±29.4 and 542.2±29.3, respectively, showing a significant reduction after treatment. Mean ACD values at baseline, and at 3mo and 6mo were, 3.00±0.43, 2.95±0.42 and 2.97±0.41, respectively, showing a significant reduction at 3mo, but not at 6mo. ACD/AL changes after treatment were similar to the ACD course. The significant changes in CCT and ACD measurements were found to be related with the POAG eyes, not with the PXG eyes, when evaluated separately.

CONCLUSION:Apart from a substantial reduction in IOP, latanoprost induces corneal thinning and ACD reduction at the short term of treatment in eyes with open angle glaucoma.